Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer.

Cancer biomarkers : section A of Disease markers - 4 Mar 2016

Ribeiro Karen Bento, da Silva Zanetti Juliana, Ribeiro-Silva Alfredo, Rapatoni Liane, de Oliveira Harley Francisco, da Cunha Tirapelli Daniela Pretti, Garcia Sergio Britto, Feres Omar, da Rocha José Joaquim Ribeiro, Peria Fernanda Maris

Abstract excerpt

INTRODUCTION: Multiple stages of carcinogenesis in colon cancer encompass subpopulations of cancer stem cells (CSC), responsible for tumor cell transformation, growth and proliferation. CD44 and CD166 proteins are CSC markers associated with cell signaling, adhesion, migration, metastasis and lymphocytic response. The expression of CSC may be modulated by some factors, such as the KRAS gene mutation. OBJECTIVE:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms
Share to Hyaluronan Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Neoplasm Metastasis

Share to Neoplastic Stem Cells

Share to Patient Outcome Assessment

Share to Proportional Hazards Models

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 27062566
DOI: 10.3233/CBM-160592
PMCID: PMC13016524

Genes

CD44
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer.PMID 27062566Read ↗

Clinicopathological Features of KRAS-Mutated Colon Cancer: An Analytical Cross-Sectional StudySemantic proximity Read ↗

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal CancerSemantic proximity Read ↗

CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients.Semantic proximity Read ↗

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.Semantic proximity Read ↗

The Impact of KRAS Mutation on the Presentation and Prognosis of Non-Metastatic Colon Cancer: an Analysis from the National Cancer Database.Semantic proximity Read ↗

KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome.Semantic proximity Read ↗

Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.Semantic proximity Read ↗

Prognostic significance of CD44 variant 2 upregulation in colorectal cancerSemantic proximity Read ↗

KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.Semantic proximity Read ↗

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.Semantic proximity Read ↗

KRAS status predicts response to cetuximab for metastatic colorectal cancer.Semantic proximity Read ↗

P4HA2 involved in SLUG-associated EMT predicts poor prognosis of patients with KRAS-positive colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.